.jpg)
1 hour ago
3
Article content
Donor-supported study will evaluate whether prostate cancer radiation treatments can be safely reduced from five sessions to two
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
LETHBRIDGE, Alberta, Sept. 16, 2026 (GLOBE NEWSWIRE) — The Jack Ady Cancer Centre is hosting a clinical trial evaluating whether radiation treatments can be safely reduced for prostate cancer patients in southern Alberta. It is the first time in Alberta’s history that a cancer centre outside of Calgary or Edmonton is hosting a researcher-led cancer clinical trial.
Article content
Article content
Article content
Traditionally, prostate cancer radiation can involve up to 39 daily treatments over several weeks. A newer technique gaining widespread acceptance reduces this to five treatments, delivered once weekly. The new clinical trial takes the next step, exploring whether treatment can be safely reduced from five sessions down to just two for select patients.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
This donor-supported clinical trial was made possible through a significant contribution from the Chinook Regional Hospital Foundation, in partnership with the Alberta Cancer Foundation. The trial represents a significant step forward in expanding access to cancer research and innovation outside Alberta’s largest cities.
Article content
“This clinical trial is an example of what a community of donors can make possible,” says Wendy Beauchesne, CEO of the Alberta Cancer Foundation. “Albertans give because they want to see better outcomes for patients and continued advances in cancer care. Their generosity is helping make innovative, patient-focused research possible right here in southern Alberta.”
Article content
“This is the first cancer clinical trial operating out of Lethbridge and is a major milestone for the region,” says Crystal Elliott, CEO of the Chinook Regional Hospital Foundation. “We are incredibly proud to support this trial that will improve access for rural and regional patients, reducing the need to travel long distances for advanced cancer care and participation in vital research.”
Article content
Article content
The initiative aligns with the Government of Alberta’s 10-year strategy to expand clinical trial access across the province, ensuring patients outside major metropolitan areas can access cutting-edge research.
Article content
“This first-of-its-kind clinical trial is great news for Alberta,” says Adriana LaGrange, Minister of Hospital and Surgical Health Services. “Alberta is becoming a leader in cancer care, and by expanding opportunities for clinical research, we are helping ensure more Albertans can benefit from the latest advances in prostate cancer treatment.”
Article content
The trial will use MRI scans to assess how a patient’s tumour responds after the first radiation dose. That response will then be used to customize the second treatment, incorporating each patient’s own biological response to radiation, rather than relying solely on a one-size-fits-all approach.
Article content
“The long-term goal is to deliver the right dose, to the right place, at the right time for each patient,” says Dr. Charles Kirkby, a Senior Medical Physicist at the Jack Ady Cancer Centre and principal investigator of the study. “This project represents a shift toward more precise, image-guided cancer care. If successful, it could redefine how prostate cancer radiotherapy is delivered, making treatment shorter, more individualized and potentially more effective without compromising safety.”
English (US)